Ó³»­´«Ã½

By matching cells' growth trajectories to their genetic features, a team finds CLL cells' arc of growth is written into their genes early in disease development.

By probing the molecular basis of proteasome inhibitor resistance in cancer cells, a Ó³»­´«Ã½-led team finds new vulnerability — and compounds that exploit it.

Researchers take a broad, multi-faceted look at a large collection of cancer cell lines, creating a new trove of data to explore for drug development opportunities.

Molecular clues to microbes and multiple cancers.

A systems biology look at how the human body changes after birth, key insights into cancer, investigating ancient Iberia, and more.

New map connects the dots in cellular reprogramming, genetic insights into sleep timing preferences, immune cells sorted with microfluidics and more.

Biopsies taken before and after treatment reveal new resistance route, as well as an opportunity to resensitize metastatic breast cancers to therapy.

Using a new model dubbed DEMETER2, the Ó³»­´«Ã½'s Cancer Dependency Map team has compiled the largest dataset of genetic dependencies in cancer to date.

Laboratory study suggests that thalidomide-like drugs could be designed to target a broad array of transcription factors, and open a new landscape of cancer drug development.